Related Experiment Videos
Rituximab therapy for severe refractory chronic Henoch-Schönlein purpura
Katherine J Donnithorne1, T Prescott Atkinson, Claas H Hinze
1University of Alabama at Birmingham School of Medicine, Birmingham, AL, USA.
Abstract:
To report on the efficacy of rituximab (RTX) therapy in standard treatment-refractory, chronic Henoch-Schönlein purpura, a retrospective chart review of 3 pediatric patients treated with RTX for severe refractory chronic Henoch-Schönlein purpura was performed. All 3 patients responded to 1 or 2 courses of RTX without serious adverse events.
Related Concept Videos
Rheumatic Heart Disease III: Medical Management
Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies
Rheumatic Heart Disease I: Introduction
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Rheumatic Heart Disease IV: Nursing Management